Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 641

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 641
---
 Company’s statement of operations for the periods presented as follows:

|                                  | Expense Category |   |   2023 |     |   |    2022 |
|:---------------------------------|:-----------------|:--|-------:|:----|:--|--------:|
| Research & Development Expense   |                  | $ | 28,437 |     | $ | 129,214 |
| General & Administrative Expense |                  |   |  5,611 |     |   |  47,948 |
| Total                            |                  | $ | 34,048 |     | $ | 177,162 |

As of December 31, 2023, there was no further compensation expense yet to be recognized related to stock options.

| F-116 |

<div align='center'>CEREVAST MEDICAL, INC.

NOTES TO FINANCIAL STATEMENTS</div>

Note 8 – Loss per Common Share

The following table presents the computation of basic and diluted net loss per share attributable to common stockholder’s:

|                                                         |     | Year Ended December 31, 
 2023                    |           |   |     | 2022 |            |   |
|:--------------------------------------------------------|:----|:------------------------|----------:|:--|:----|:-----|-----------:|:--|
| Numerator:                                              |     |                         |           |   |     |      |            |   |
| Net Loss                                                |     | $                       |   (75,532 | ) |     | $    | (1,260,267 | ) |
| Denominator:                                            |     |                         |           |   |     |      |            |   |
| Weighted average shares outstanding - basic and diluted |     |                         | 1,976,201 |   |     |      |  1,976,201 |   |
| Basic and diluted net loss per common share             |     | $                       |     (0.04 | ) |     | $    |      (0.64 | ) |

Note 9 – Income Taxes

Cerevast is subject to US federal income taxes at a statutory rate of 21%. Income tax expense is composed of the following:

|                          |     |   | 2023 |     |   | Year Ended December 31, 
 2022                    |
|:-------------------------|:----|:--|:-----|:----|:--|:----------------